Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

CDC reported an additional 70 cases.

  • Read more about CDC reported an additional 70 cases.

CDC reported a further 36 cases.

  • Read more about CDC reported a further 36 cases.

A British Medical Journal editorial referred to post-transfusion hepatitis as "the major complication of the modern treatment of haemophilia".

  • Read more about A British Medical Journal editorial referred to post-transfusion hepatitis as "the major complication of the modern treatment of haemophilia".

Dr Diana Walford described NANBH as a form of hepatitis that could "be rapidly fatal" or "lead to progressive liver damage".

  • Read more about Dr Diana Walford described NANBH as a form of hepatitis that could "be rapidly fatal" or "lead to progressive liver damage".

Dr Peter Kernoff wrote to Dr Brian Colvin describing NANBH as "a serious disease with long-term consequences".

  • Read more about Dr Peter Kernoff wrote to Dr Brian Colvin describing NANBH as "a serious disease with long-term consequences".

The Lancet published a study by Dr Eric Preston and others showing chronic liver disease in patients with haemophilia treated with factor concentrates.

  • Read more about The Lancet published a study by Dr Eric Preston and others showing chronic liver disease in patients with haemophilia treated with factor concentrates.

An article by Dr Harvey Alter emphasised that NANBH could progress to chronic hepatitis.

  • Read more about An article by Dr Harvey Alter emphasised that NANBH could progress to chronic hepatitis.

An article by Dr Jay Hoofnagle and others emphasised that NANBH could progress to chronic hepatitis and was linked to persistent liver damage.

  • Read more about An article by Dr Jay Hoofnagle and others emphasised that NANBH could progress to chronic hepatitis and was linked to persistent liver damage.

Dr Jay Hoofnagle and others wrote that until the nature of NANBH was "elucidated", blood and blood products should be considered as potentially infectious.

  • Read more about Dr Jay Hoofnagle and others wrote that until the nature of NANBH was "elucidated", blood and blood products should be considered as potentially infectious.

Dr Harvey Alter and others wrote that the long-term prognosis of NANBH may be similar to that of Hepatitis B.

  • Read more about Dr Harvey Alter and others wrote that the long-term prognosis of NANBH may be similar to that of Hepatitis B.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 817
  • Page 818
  • Page 819
  • Page 820
  • Current page 821
  • Page 822
  • Page 823
  • Page 824
  • Page 825
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.